Download FREE Report Sample
Download Free sampleUstekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.
Ustekinumab Market contains market size and forecasts of Ustekinumab in global, including the following market information:
Global Ustekinumab Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Ustekinumab Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Ustekinumab companies in 2021 (%)
The global Ustekinumab market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Intravenous Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Ustekinumab include Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi Tanabe, Stada, EPIRUS BioPharma, Formycon and NeuClone, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Ustekinumab manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ustekinumab Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ustekinumab Market Segment Percentages, by Type, 2021 (%)
Intravenous
Subcutaneous
Global Ustekinumab Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ustekinumab Market Segment Percentages, by Application, 2021 (%)
Arthritis
Colitis
Lupus Erythematosus
Myositis Multiplex With Palmoplantar Pustulosis
Cirrhosis Of The Liver
Sarcoidosis
Diabetes
Other
Global Ustekinumab Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ustekinumab Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ustekinumab revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Ustekinumab revenues share in global market, 2021 (%)
Key companies Ustekinumab sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Ustekinumab sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Meiji
Johnson & Johnson
Alvotech
Fuji Pharma
Mitsubishi Tanabe
Stada
EPIRUS BioPharma
Formycon
NeuClone
Outlook Therapeutics
Harvest Moon Pharma
BioXpress
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
